

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Krishna Institute of Medical Sciences Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Krishna Institute of Medical Sciences Limited (the "Company") for the quarter ended 30 June 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

Other matters


5. The Statement includes the results for the corresponding quarter ended 30 June 2020 and for the previous quarter 31 March 2021 as reported in these Unaudited Financial Results have been prepared solely based on the information compiled by the management, and have not been subject to audit or review.

Our conclusion on the Statement is not modified in respect of this matter.

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004



per Navneet Rai Kabra

Partner

Membership No.: 102328

UDIN: 21102328AAAAFB9445

Hyderabad

10 August 2021



Krishna Institute of Medical Sciences Limited

Corporate Identity number : U55101TG1973PLC040558

Registered office : 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India

Website: www.kimshospitals.com, Email: cs@kimshospitals.com, Tel: 040 7122 5000

Statement of Unaudited Standalone Financial Results for the quarter ended 30 June 2021

(Rupees in millions)

S.No.	Particulars	Quarter Ended			Year ended
		30-Jun-21	31-Mar-21	30-Jun-20	31-Mar-21
		(Unaudited)	(Unaudited) Refer note 2	(Unaudited) Refer note 2	(Audited)
1	Income				
	(a) Revenue from operations	3,315.14	2,566.29	1,395.55	9,326.89
	(b) Other income	40.17	36.19	38.11	96.15
	Total Income	3,355.31	2,602.48	1,433.66	9,423.04
2	Expenses				
	(a) Purchase of medical consumables, drugs and surgical instruments	864.77	541.21	300.10	1,959.62
	(b) Decrease / (increase) in inventories of medical consumables, drugs and surgical instruments	(55.88)	(2.75)	7.07	52.34
	(c) Employee benefits expense	492.20	379.17	306.61	1,470.36
	(d) Other expenses	903.09	804.54	444.02	2,804.28
	(e) Finance cost	22.49	31.08	45.37	147.83
	(f) Depreciation and amortisation expense	107.36	105.51	103.43	445.98
	Total Expenses	2,334.03	1,858.76	1,206.60	6,880.41
3	Profit before tax (1-2)	1,021.28	743.72	227.06	2,542.63
4	Tax expense				
	(a) Current tax	263.54	204.78	55.54	668.12
	(b) Deferred tax charged/(credit)	(3.88)	7.95	1.60	(1.64)
	(c) Adjustment of tax relating to earlier periods	-	-	-	(10.34)
	Total tax expenses	259.66	212.73	57.14	656.14
5	Profit for the period/year (3-4)	761.62	530.99	169.92	1,886.49
6	Other comprehensive income				
	Items that will not be reclassified subsequently to statement of profit and loss				
	- Re-measurement (loss)/gain on defined benefit plans	(1.60)	7.95	(3.02)	(6.40)
	- Income tax effect	0.40	(2.00)	0.76	1.61
	Other comprehensive income, net of tax	(1.20)	5.95	(2.26)	(4.79)
7	Total comprehensive income for the period/year (5+6)	760.42	536.94	167.66	1,881.70
8	Paid up equity share capital (face value of Rs.10 each)				775.93
9	Other Equity				8,297.30
10	Earnings / (Loss) per share (of Rs.10 each) : (not annualised for the quarter ended)				
	(a) Basic (Rs.)	9.81	7.09	2.28	25.20
	(b) Diluted (Rs.)	9.81	6.97	2.26	24.77



Notes:

- 1 In terms of Regulation 33 of the SFBI (Listing Obligations and Disclosure Requirements) 2015, this Statement of Unaudited Standalone Financial Results for the quarter ended 30 June 2021 ("Unaudited Standalone Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10 August 2021 and have been subject to a limited review by the statutory auditors of the Company. An unqualified report was issued by them thereon.
- 2 The Unaudited Standalone financial results for the corresponding quarter ended 30 June 2020 and for the preceding quarter ended 31 March 2021, have not been subject to an audit or review by our statutory auditors. However, the management has exercised necessary due diligence to ensure that the Unaudited Standalone financial results for these periods provide a true and fair view of the Company's affairs.
- 3 The Unaudited Standalone Financial Results of the Company have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, as amended (the "Listing requirements").
- 4 The Company has completed Initial Public Offer ("IPO") of 25,995,042 Equity Shares of the face value of Rs. 10/- each at an issue price of Rs. 825/- per Equity Share, comprising offer for sale of 23,560,538 shares by Selling Shareholders and fresh issue of 2,434,504 shares. The Equity Shares of the Company were listed on BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") on 28 June 2021. Accordingly, the Unaudited Standalone Financial Results for the quarter ended 30 June 2021 are drawn up for the first time in accordance with the Listing requirements.
- 5 The utilisation of the net IPO proceeds is summarised below:

Particulars	Objects of the issue as per prospectus *	Utilisation upto 30 June 2021	Unutilised amount as on 30 June 2021
Repayment/pre-payment, in full or part, of certain borrowings availed by our Company and by our Subsidiaries	1,500.00	-	1,500.00
General Corporate Purpose	416.60	-	416.60
Total	1,916.60	-	1,916.60

* net of Offer expenses to the extent applicable to the Fresh Issue.

IPO Proceeds, unutilised as at 30 June 2021, were temporarily invested in monitoring agency account.

- 6 The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/interpretation have not yet been issued. The Company is assessing the impact of the Code and will record any related impact in the period of the Code becomes effective.
- 7 The Company operates in one single reportable business segment - "Medical and Healthcare services".
- 8 The outbreak of COVID-19 in many countries has brought about disruptions to businesses around the world and uncertainty to the global economy. The Company is closely monitoring the impact of the pandemic on all aspects of its business, including how it will impact its employees, vendors and business partners. The Company based on the information available to date, both internal and external, considered the uncertainty relating to the COVID-19 pandemic in assessing its impact. Based on the current estimates, the Company expects to fully recover the carrying amount of assets, and does not foresee any material adverse impact on its operations. As the outbreak continues to evolve, the Company will continue to closely monitor any material changes to future economic condition.
- 9 The above Unaudited Standalone Financial Results of the Company are available on the Company's website www.kimshospitals.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.

For and on behalf of the Board
Krishna Institute of Medical Sciences Limited



[Signature]
Dr. B Bhaskara Rao
Managing Director
DIN: 00008985

Hyderabad
10 August 2021

